Compare

Cerenome, Inc. vs ProPhase Labs, Inc. vs China Pharma Holdings, Inc. vs Immunome Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCerenome, Inc.
CNSY
ProPhase Labs, Inc.
PRPH
China Pharma Holdings, Inc.
CPHI
Immunome Inc.
IMNM
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$5.21M$4.34M$4.14M$6.94M
Revenue growth (YoY)-10.5%-35.8%-8.5%-23.2%
Gross marginn/a31.9%-3.2%n/a
Operating margin-293.5%-415.4%-78.2%n/m
Net margin-429.4%-339.3%-76.9%n/m
Net income-$22.39M-$14.74M-$3.19M-$212.39M
EPS (Diluted)-$0.29-$1.74-$0.74-$2.43
Operating cash flow-$20.77M-$8.34M$148.3K-$190.92M
Free cash flow-$20.84M-$8.34M$88.9K-$200.60M
Cash & equivalents$4.26M$90.0K$345.1K$653.48M
Total assets$16.32M$59.87M$31.00M$683.19M
Total liabilities$12.33M$56.36M$8.26M$48.84M
Shareholders' equity$4.00M$3.51M$22.74M$634.34M
Return on year-end equity-560.2%-420.3%-14.0%-33.5%
Shares outstanding138.68M8.97M15.52M113.13M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCerenome, Inc.ProPhase Labs, Inc.China Pharma Holdings, Inc.Immunome Inc.
Latest$5.21M
Ended 2025-12-31
$4.34M
Ended 2025-12-31
$4.14M
Ended 2025-12-31
$6.94M
Ended 2025-12-31
1 year earlier$5.82M
Ended 2024-12-31
$6.77M
Ended 2024-12-31
$4.53M
Ended 2024-12-31
$9.04M
Ended 2024-12-31
2 years earlier$4.91M
Ended 2023-12-31
$34.98M
Ended 2023-12-31
$7.01M
Ended 2023-12-31
$14.02M
Ended 2023-12-31
3 years earliern/a$122.65M
Ended 2022-12-31
$8.10M
Ended 2022-12-31
n/a
4 years earliern/a$79.04M
Ended 2021-12-31
$9.64M
Ended 2021-12-31
n/a